Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Breast Cancer
Breast Cancer
New Antibody–Drug Conjugates in Breast Cancer
Read More
Breast Cancer
Advancements in Targeted Therapy and Immunotherapy for Human Breast Cancer
Read More
Breast Cancer
Latest Updates on Targeted Therapy in HR-Positive and HER2-Negative Breast Cancer
Read More
Breast Cancer
Resistance Mechanisms to CDK4/6 Blockade in Advanced HR-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities
Read More
Breast Cancer
Olaparib Monotherapy in Triple-Negative Breast Cancer
Read More
Breast Cancer
2021 Breast Cancer Year in Review Introduction
Read More
Breast Cancer
Dalpiciclib plus Fulvestrant in HR-Positive and HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Palbociclib in Combination with Aromatase Inhibitors in Elderly Patients with Estrogen Receptor–Positive and HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Olaparib as Adjuvant Therapy in Patients with BRCA1 or BRCA2 Mutation–Positive Breast Cancer
Read More
Breast Cancer
Olaparib’s OlympiA Trial Crossed the Superiority Limit for Invasive Disease-Free Survival versus Placebo
Read More
1
2
3
4
5
6
Page 3 of 11
Results 21 - 30 of 101